Why is Alström syndrome often diagnosed late?

One of the hardest and most painful parts of Alström syndrome for many families is not just the diagnosis itself, but how long it can take to reach it. Parents often spend years noticing that something is wrong, seeing multiple specialists, and still not getting a clear answer. That experience is so common that it is worth asking directly: why is Alström syndrome often diagnosed late?

The short answer is that Alström syndrome is rare, progressive, and often unfolds in stages. The earliest symptoms may look like separate problems rather than one connected syndrome. A child may first be seen for visual impairment, then later for weight gain, hearing changes, cardiomyopathy, diabetes risk, liver disease, or kidney issues. When those features are spread across time and across different clinics, diagnosis can be delayed for years.

A 2024 research report on the journey to diagnosis in Alström syndrome gives us especially useful data on this problem. In that UK sample, only 18 percent of patients were diagnosed between 3 months and 1 year after symptom onset. Even more striking, 41 percent waited more than 5 years after first symptoms before receiving a diagnosis. That is a major diagnostic delay in a condition where early surveillance can matter a lot.

The first reason diagnosis is often late is simple. Alström syndrome is ultra-rare. The report describes prevalence as around 1 in a million. Most general clinicians will never knowingly diagnose a case. Even many specialists may not have direct experience with it. When a disorder is that uncommon, it is easier for familiar explanations to crowd out the correct one.

This does not mean doctors are careless. It means rare disease diagnosis is vulnerable to pattern-recognition failure. If a clinician has never seen Alström syndrome before, they are more likely to interpret symptoms through more common diagnoses first.

Another major reason for delayed diagnosis is that Alström syndrome does not usually present as a neat full picture at birth. Visual problems may begin in infancy, often through nystagmus, photophobia, and retinal dysfunction. Hearing loss may emerge later. Obesity and rapid weight gain may become clearer in the first year or soon after. Insulin resistance, diabetes, liver disease, kidney disease, and broader metabolic complications can become more obvious over time.

That staged presentation creates a classic diagnostic trap. The first symptom is treated as one issue, the next as another, and only later does the whole pattern become visible. The report supports this reality by showing that diagnosis was quicker in patients with both visual impairment and cardiomyopathy, but slower in those with visual impairment alone and no other obvious early symptoms.

The report found that the most common route to diagnosis was through ophthalmology referral. That makes clinical sense. Retinal dystrophy and early visual dysfunction are often among the first clues. If a child presents to ophthalmology with severe early visual problems, this may become the first point where a syndromic explanation is considered.

But this also reveals a weakness in the system. If ophthalmology is the main route in, then children whose visual presentation is recognised but not connected to multisystem red flags may still experience delay. Put simply, seeing the eyes is not enough. Someone has to connect the eye findings to the broader body pattern.

One of the most useful observations from the report is that patients with visual impairment and no other obvious symptoms waited longer for an Alström syndrome diagnosis. This is important for families because it explains a very common experience. A child may clearly have something wrong with their vision, but if there is not yet obvious cardiomyopathy, obesity, or metabolic disease, rare syndrome testing may not happen quickly.

This does not mean visual signs are weak clues. They are important clues. The issue is that early isolated-looking vision symptoms may not be enough to trigger the right genetics pathway without stronger syndromic suspicion.

The paper also found that patients with visual impairment and cardiomyopathy were diagnosed much more quickly, often in infancy or early childhood. Cardiovascular disease was one of the three first symptoms in over half of the sample, and cardiac gene panels led to diagnosis in a subset of patients after early-life cardiovascular presentation.

This tells us something useful. When the syndrome appears as a dramatic symptom cluster, especially vision plus heart disease, the pathway becomes clearer. It is the quieter or more staggered presentations that are most likely to be missed.

One of the strongest practical messages in the paper is that rapid obesity or excessive weight gain in infancy should be treated as a key red flag. More than half of the sample presented with excessive weight gain, and the majority experienced rapid weight gain in the first year of life. The authors argue that this symptom should be flagged earlier when Alström syndrome is a possible diagnosis.

This matters because early obesity is often explained away in isolation. But in a child with visual impairment, nystagmus, or cardiomyopathy, rapid infant weight gain should change the level of suspicion. It is part of the syndrome pattern, not background noise.

The report is clear that delayed diagnosis can have devastating and even life-threatening consequences. That is not dramatic wording for effect. It reflects the fact that Alström syndrome can involve cardiomyopathy, diabetes, liver disease, and kidney disease, all of which may need structured surveillance. When diagnosis is delayed, those systems may not be monitored early enough.

Families also pay a major emotional price. Years of fragmented explanations, repeated appointments, and missed opportunities create stress that is hard to overstate. Diagnostic delay is not only a medical problem. It is also a family burden problem.

Another finding from the paper is that the Covid-19 pandemic exacerbated delays and missed diagnostic opportunities. That matters because it reminds us diagnostic delay is not always about the syndrome alone. Health system disruption can widen the gaps even further, especially for rare conditions that already rely on careful referrals and coordinated specialist review.

The strongest practical recommendation from the paper is that standardised pathways should improve the diagnostic odyssey for patients and families. In real terms, that means better recognition of red-flag symptom clusters, earlier genetics referral, and stronger awareness across ophthalmology, cardiology, paediatrics, and weight-management settings.

The report specifically suggests that obesity developing rapidly in infancy should be flagged more clearly, and that visual impairment together with cardiomyopathy is a particularly important presentation pattern. Those are exactly the kinds of clues that should guide a better referral protocol.

Families cannot fix a weak system on their own, but they can ask better questions. If a child has early visual impairment plus rapid weight gain, hearing changes, cardiomyopathy, or unusual multisystem involvement, it is reasonable to ask whether Alström syndrome has been considered specifically. It is also reasonable to ask whether ALMS1 testing or broader genetic testing is appropriate.

Parents often notice the pattern before anyone else names it. That should not be underestimated.